Navigation Links
Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
Date:3/16/2010

Under the Hatch-Waxman Act, Shire has 45 days from the receipt of the Notice Letter to determine if it will file a patent infringement suit. If Shire brings suit pursuant to the Hatch Waxman regulations, a stay of approval of up to 30-months will be imposed by the FDA on Teva's ANDA.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.


'/>"/>
SOURCE Shire Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shire Supports Rare Disease Day 2010
2. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
3. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
4. Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
5. New Shire Board Member
6. Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
7. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
8. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
9. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
10. Shire Initiates Two Adult ADHD Outreach Programs
11. Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... MARLBOROUGH, Mass. , June 2, 2015 ... ), a biotechnology company focused on discovering ... areas of dermatology and ophthalmology, today announced that ... Development Officer, will present at the 23 ... This six-day world congress will include in-depth ...
(Date:6/2/2015)... GLASGOW, Scotland , June 2, 2015 /PRNewswire/ ... of addressing the global antibiotic resistance problem  ... truly novel class of anti-infectives, to address the ... that it has developed a stable intravenous (IV) ... susceptible and resistant Gram-positive hospital-acquired infections.  The ...
(Date:6/1/2015)... June 1, 2015 ... announced the addition of the "Oxidative ... Services), Test Type (Indirect, Enzyme-based, Reactive Oxygen ... End Users - Global Forecast to 2020" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , The ...
(Date:6/1/2015)... , June 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... March 31, 2015.  Biorem,s complete 2015 first quarter financial statements and ... Financial Summary:Three-months ended March 31,(in CDN$,000 except per share ... 4,689 , 1,974 Gross profit , 1,531 ... Net earnings (loss) , 528 , (531) Basic ...
Breaking Biology Technology:RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3
... Quest PharmaTech Inc.,("Quest" or the "Company") is ... support from NRC-IRAP towards the development of ... Sonodynamic Therapy arises out of the Company,s ... and skin diseases. The,Company,s lead compound, SL017, ...
... of Origin Test Aids in the Diagnosis of Uncertain ... ... Calif., April 22 Pathwork Diagnostics, Inc.,a genomics-based diagnostics company focused ... Test through its CLIA-certified,Pathwork(R) Diagnostics Laboratory. The new test aids in ...
... MEDX ) announced today that it is scheduled ... at 10:30 a.m. EDT on,Wednesday, April 30, 2008. The ... the Investor Relations section of the Medarex website at, ... be available,following the event., About Medarex, Medarex ...
Cached Biology Technology:Quest PharmaTech Receives Support from National Research Council's Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer 2Pathwork(R) Diagnostics Launches Genomics-Based Test For Hard-To-Identify Tumors Through Its CLIA-Certified Laboratory 2Pathwork(R) Diagnostics Launches Genomics-Based Test For Hard-To-Identify Tumors Through Its CLIA-Certified Laboratory 3Medarex to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2
(Date:5/21/2015)... The Sync Project™ , a global ... today announced a collaborative partnership with Berklee,s Institute ... on collaboration on original research, joint course development and ... collaboration, The Sync Project and BerkleeICE are exploring the ... the 2015-2016 academic year.  The course ...
(Date:5/19/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/18/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... University of Michigan researchers and their colleagues recently hastened ... trees in a large-scale, long-term experiment to glimpse the ... bark was stripped from each tree to kill it ... the federally funded experiment Forest Accelerated Succession Experiment (FASET) ...
... of Pacific Islands Forestry have submitted a proposal to ... strawberry guava, a South American tree that has invaded ... in 1825 as a garden plant. The scientists are ... and Natural Resources, and Hawai Department of Agriculture, agencies ...
... May 25, 2008, approaching 5 p.m. PDT, NASA scientists will ... because at that time the Phoenix Mars Mission space vehicle ... a soft landing onto the northern Mars terrain called Green ... the Red Planet. The place got its name after analysis ...
Cached Biology News:U-M scientists remove thousands of aspens to glimpse forest's future 2U-M scientists remove thousands of aspens to glimpse forest's future 3Insect release proposed to control exotic strawberry guava 2Phoenix mission to Mars will search for climate clues 2Phoenix mission to Mars will search for climate clues 3
... Blot includes 7 lanes ... from Alzheimer's-diseased brain tissue ... gyrus, frontal lobe, temporal ... lobe and cerebellum. Patent/trademark/license ...
... use spatulas have been designed to save ... for those interested in eliminating the recycling ... spatula is individually packaged, RNase/DNase free, non-pyrogenic ... a new product number, created to easily ...
... for the mechanical harvesting of cells • ... even contact with the growth surface • ... flasks • Individually wrapped • Sterilized by ... CLS number is a new product number, ...
... Corning single use spatulas have been ... samples. They are for those interested in ... reusable spatulas. Each spatula is individually packaged, ... CLS number is a new product number, ...
Biology Products: